1 |
Sharma P , Goswami S , Raychaudhuri D , Siddiqui BA , Singh P , Nagarajan A , Liu J , Subudhi SK , Poon C , Gant KL , Herbrich SM , Anandhan S , Islam S , Amit M , Anandappa G , Allison JP . Immune checkpoint therapy: current perspectives and future directions. Cell, 2023, 186: 1652- 1669.
doi: 10.1016/j.cell.2023.03.006
|
2 |
Abril-Rodriguez G , Ribas A . SnapShot: immune checkpoint inhibitors. Cancer Cell, 2017, 31: 848- 848. e1.
doi: 10.1016/j.ccell.2017.05.010
|
3 |
Farina A , Villagrán-García M , Vogrig A , Zekeridou A , Muñiz-Castrillo S , Velasco R , Guidon AC , Joubert B , Honnorat J . Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol, 2024, 23: 81- 94.
doi: 10.1016/S1474-4422(23)00369-1
|
4 |
Johnson DB , Nebhan CA , Moslehi JJ , Balko JM . Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol, 2022, 19: 254- 267.
doi: 10.1038/s41571-022-00600-w
|
5 |
Wang SJ , Dougan SK , Dougan M . Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer, 2023, 9: 543- 553.
doi: 10.1016/j.trecan.2023.04.002
|
6 |
Haanen J , Obeid M , Spain L , Carbonnel F , Wang Y , Robert C , Lyon AR , Wick W , Kostine M , Peters S , Jordan K , Larkin J , ESMO Guidelines Committee . Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol, 2022, 33: 1217- 1238.
doi: 10.1016/j.annonc.2022.10.001
|
7 |
Postow MA , Sidlow R , Hellmann MD . Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med, 2018, 378: 158- 168.
doi: 10.1056/NEJMra1703481
|
8 |
Marini A , Bernardini A , Gigli GL , Valente M , Muñiz-Castrillo S , Honnorat J , Vogrig A . Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology, 2021, 96: 754- 766.
doi: 10.1212/WNL.0000000000011795
|
9 |
Fan SY , Guan HZ , Ren HT , Xu Y , Wang MZ , Zhao L , Gao J , Peng B , Cui LY . Immune checkpoint inhibitor associated aseptic meningitis: a case report and review of the literature. Zhonghua Shen Jing Ke Za Zhi, 2021, 54: 106- 111.
|
|
范思远, 关鸿志, 任海涛, 徐燕, 王孟昭, 赵珞, 高晶, 彭斌, 崔丽英. 免疫检测点抑制剂相关无菌性脑膜炎一例并文献复习. 中华神经科杂志, 2021, 54: 106- 111.
|
10 |
Fonseca E , Cabrera-Maqueda JM , Ruiz-García R , Naranjo L , Diaz-Pedroche C , Velasco R , Macias-Gómez A , Milisenda JC , Muñoz-Farjas E , Pascual-Goñi E , Gállego Perez-Larraya J , Saiz A , Dalmau J , Blanco Y , Graus F , Martinez-Hernandez E , Neuro-ICI-Spain Study Group . Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study. Lancet Neurol, 2023, 22: 1150- 1159.
doi: 10.1016/S1474-4422(23)00335-6
|
11 |
Velasco R , Villagrán M , Jové M , Simó M , Vilariño N , Alemany M , Palmero R , Martínez-Villacampa MM , Nadal E , Bruna J . Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol, 2021, 78: 864- 873.
doi: 10.1001/jamaneurol.2021.0249
|
12 |
Duong SL , Prüss H . Paraneoplastic autoimmune neurological syndromes and the role of immune checkpoint inhibitors. Neurotherapeutics, 2022, 19: 848- 863.
doi: 10.1007/s13311-022-01184-0
|
13 |
Graus F , Vogrig A , Muñiz-Castrillo S , Antoine JG , Desestret V , Dubey D , Giometto B , Irani SR , Joubert B , Leypoldt F , McKeon A , Prüss H , Psimaras D , Thomas L , Titulaer MJ , Vedeler CA , Verschuuren JJ , Dalmau J , Honnorat J . Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm, 2021, 8: e1014.
doi: 10.1212/NXI.0000000000001014
|
14 |
|
15 |
Williams TJ , Benavides DR , Patrice KA , Dalmau JO , deÁvila AL , Le DT , Lipson EJ , Probasco JC , Mowry EM . Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol, 2016, 73: 928- 933.
doi: 10.1001/jamaneurol.2016.1399
|
16 |
Shah N , Jacob J , Househ Z , Shiner E , Baird L , Soudy H . Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab. J Immunother Cancer, 2019, 7: 247.
doi: 10.1186/s40425-019-0727-5
|
17 |
Segal Y , Bukstein F , Raz M , Aizenstein O , Alcalay Y , Gadoth A . PD-1-inhibitor-induced PCA-2(MAP1B) autoimmunity in a patient with renal cell carcinoma. Cerebellum, 2022, 21: 328- 331.
doi: 10.1007/s12311-021-01298-9
|
18 |
Farina A , Villagrán-García M , Ciano-Petersen NL , Vogrig A , Muñiz-Castrillo S , Taillandier L , Michaud M , Lefilliatre M , Wang A , Lepine Z , Picard G , Wucher V , Dhairi M , Fabien N , Goncalves D , Rogemond V , Joubert B , Honnorat J . Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm, 2022, 10: e200058.
|
19 |
Dubey D , David WS , Reynolds KL , Chute DF , Clement NF , Cohen JV , Lawrence DP , Mooradian MJ , Sullivan RJ , Guidon AC . Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol, 2020, 87: 659- 669.
doi: 10.1002/ana.25708
|
20 |
Wang L , Lou H , Li B , Li J , Yang YM . Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer. Invest New Drugs, 2022, 40: 151- 156.
doi: 10.1007/s10637-021-01154-x
|
21 |
Graus F , Dalmau J . Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol, 2019, 16: 535- 548.
doi: 10.1038/s41571-019-0194-4
|
22 |
Vogrig A , Muñiz-Castrillo S , Desestret V , Joubert B , Honnorat J . Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Ther Adv Neurol Disord, 2020, 13: 1- 15.
|
23 |
Matsuoka H , Kimura H , Koba H , Tambo Y , Ohkura N , Hara J , Sone T , Kasahara K . Nivolumab-induced limbic encephalitis with anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer, 2018, 19: e597- e599.
doi: 10.1016/j.cllc.2018.04.009
|
24 |
Kopecký J , Kubeček O , Geryk T , Slováčková B , Hoffmann P , Žiaran M , Priester P . Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. J Med Case Rep, 2018, 12: 262.
doi: 10.1186/s13256-018-1786-9
|
25 |
Committee of Neoplastic Supportive-Care, China Anti-Cancer Association , Cancer Clinical Chemotherapy Committee, China Anti-Cancer Association . Chinese expert consensus on diagnosis and treatment of neurologic immune-related adverse events associated with immune checkpoint inhibitors (2022 edition). Zhonghua Zhong Liu Za Zhi, 2022, 44: 935- 941.
|
|
中国抗癌协会肿瘤支持治疗专业委员会, 中国抗癌协会肿瘤临床化疗专业委员会. 免疫检查点抑制剂相关神经不良反应诊治中国专家共识(2022版). 中华肿瘤杂志, 2022, 44: 935- 941.
|
26 |
Schneider BJ , Naidoo J , Santomasso BD , Lacchetti C , Adkins S , Anadkat M , Atkins MB , Brassil KJ , Caterino JM , Chau I , Davies MJ , Ernstoff MS , Fecher L , Ghosh M , Jaiyesimi I , Mammen JS , Naing A , Nastoupil LJ , Phillips T , Porter LD , Reichner CA , Seigel C , Song JM , Spira A , Suarez-Almazor M , Swami U , Thompson JA , Vikas P , Wang Y , Weber JS , Funchain P , Bollin K . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol, 2021, 39: 4073- 4126.
doi: 10.1200/JCO.21.01440
|
27 |
Esfahani K , Elkrief A , Calabrese C , Lapointe R , Hudson M , Routy B , Miller WH Jr , Calabrese L . Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol, 2020, 17: 504- 515.
doi: 10.1038/s41571-020-0352-8
|
28 |
Nakashima K , Fujii Y , Sato M , Igarashi K , Kobayashi M , Ishizuka T . A case of non-small cell lung cancer presenting anti-amphiphysin antibody-positive paraneoplastic neurological syndrome. Respir Med Case Rep, 2021, 34: 101525.
|
29 |
Chompoopong P , Zekeridou A , Shelly S , Ruff M , Dyck PJ , Klein CJ , Pittock SJ , Mauermann M , Dubey D . Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. J Neurol Neurosurg Psychiatry, 2022, 93: 112- 114.
doi: 10.1136/jnnp-2021-326369
|